In veterinary tablet manufacture, oleic acid is encountered primarily as a liquefiable lipid binder in melt-assisted granulation rather than as a dry lubricant. A binder phase containing 5–10% w/w oleic acid in glyceryl distearate is melted at 55–65 °C and sprayed onto a fluidized powder bed. Product temperature is held at 45–50 °C during the spray phase to prevent solidification of the lipid inside the nozzle. Granules formed under these conditions pass through a 1.0 mm screen before compression. Tablet compression is performed on a rotary press with 8–32 stations at a target hardness of 40–80 N, measured according to USP 1217. Friability is assessed by USP 1216 using 6.5 g of tablets rotated for 100 revolutions. Ejection force data from instrumented single-punch presses show that oleic acid reduces wall friction when the lipid binder remains partially molten at the die wall. A fully liquid binder above 4% w/w may cause picking and weight variation because punch surfaces become oil-filmed. For this reason, the oleic acid fraction is usually kept below 2.5% w/w of the total tablet mass unless a porous excipient such as colloidal silicon dioxide at 0.5–1.0% w/w is co-processed to absorb free oil. Disintegration of lipid-bound tablets is evaluated by USP 701 in 900 mL of 0.1 M HCl at 37±0.5 °C. Rapid disintegration below 15 minutes is achievable when the lipid binder includes a water-soluble pore former such as mannitol or sorbitol. Animal-specific chewable tablets for companion animals often achieve acceptable acceptance values for content uniformity under USP 905 when the granulation yield in the 125–850 µm fraction exceeds 65%. The terminal product is a compressed veterinary tablet, typically a dewormer or palatable chewable, with loss on drying below 2.0% w/w at release. Oleic acid is not appropriate as a direct-compression aid at room temperature because its liquid state interferes with hopper flow. The material must be processed as a component of a molten lipid system or adsorbed onto a free-flowing carrier before tablet manufacture. Published data for specific oleic acid tablet binders in veterinary formulations is limited because most lipid binder work is reported in human pharmaceutical literature. Process validation therefore requires pilot-scale batches that demonstrate acceptable hardness, friability, disintegration, and content uniformity under the final marketing specification.

What Limits Terminal Sterilization Cycles in Oleic Acid-Based Injection Vehicles?

Oleic acid serves as a water-immiscible vehicle component in sterile injections for cattle and swine when the active substance is lipophilic and unstable in aqueous media. A typical anhydrous vehicle contains 10–30% w/w oleic acid in fractionated coconut oil or sesame oil, with a total oil volume of 1–10 mL per injection site. Syringeability improves because oleic acid viscosity at 25 °C is approximately 25–40 mPa·s, compared with 50–70 mPa·s for unmodified sesame oil. The vehicle is prepared in a jacketed stainless-steel vessel under nitrogen sparge. The active substance is dissolved at 40–60 °C with a recirculating homogenizer operating at 3,000–5,000 rpm. Residual moisture is controlled below 0.1% w/w by vacuum drying before filling. Terminal moist-heat sterilization at 121 °C for 15 minutes is only feasible if the peroxide value remains below 10.0 meq/kg after the cycle, measured by Ph. Eur. 2.5.5. Oxidative degradation becomes measurable at elevated headspace oxygen, and cycles beyond 125 °C are not recommended for oleic acid-rich vehicles because cis-9-octadecenoic acid isomerizes at elevated temperatures. Nitrogen flushing of the bulk solution and final vials is maintained until capping. Particulate matter is controlled to USP 788 limits for small-volume injections. Bacterial endotoxin testing follows Ph. Eur. 2.6.14, with product-specific limits derived from dose volume and target species. Sterility is confirmed by membrane filtration under Ph. Eur. 2.6.1. A common terminal product is a multidose 50–100 mL sterile injectable suspension in amber Type I glass vials with bromobutyl stoppers. Long-acting release is governed by the oil partition coefficient and injection-site encapsulation, not by polymer erosion. The ratio of oleic acid to the main oil must be confirmed in stability studies because fatty acid can extract leachables from elastomeric closures. If the active substance is highly crystalline, micronization to a D90 below 15 µm followed by high-shear suspension in the oleic acid-containing vehicle reduces caking in storage. The vehicle is tested for acid value by Ph. Eur. 2.5.1, iodine value by Ph. Eur. 2.5.4, and water content by Ph. Eur. 2.5.32. Published data for specific oleic acid-containing veterinary injectable formulations is limited because proprietary formulation details are not public. The excipient monograph provides the baseline oxidation and identity controls that a sterile manufacturing site must meet. Veterinary-grade oleic acid for parenteral use is not interchangeable with feed-grade material because oxidation products and trace metal residuals are controlled differently.

Self-Emulsifying Drench Systems Demand Phase-Boundary Monitoring

For oral administration to ruminants, oleic acid can be incorporated into a self-microemulsifying preconcentrate. A representative preconcentrate consists of 25–35% w/w oleic acid, 40–50% w/w polysorbate 80, and 15–25% w/w propylene glycol. The mixture is pre-sheared at 55–60 °C until the liquid is clear by visual inspection. Upon dilution with tap water at 37 °C, the system should form a dispersion with droplet size below 100 nm. Droplet size is determined by dynamic light scattering at a 90° angle. Phase separation is tested after 24 h at 25±2 °C. No creaming or oiling out is acceptable for a multi-dose drench container. The final oral solution is packaged in 1 L or 5 L high-density polyethylene containers. Dose volume for sheep is normally calibrated to 0.2–0.5 mL/kg body weight, but the actual dose is dictated by active substance pharmacology. The drench is delivered through a standard drench gun. Viscosity of the preconcentrate is adjusted to 80–150 mPa·s at 20 °C to permit reliable flow through the gun without cavitation. Water tolerance of the preconcentrate depends on the surfactant-to-oil ratio. At a surfactant-to-oil ratio below 1.2, the system may gel upon dilution. At a ratio above 2.0, the formulation becomes detergent-rich and can irritate the oral mucosa. Formulation scientists determine the ternary phase diagram by conductivity and light transmittance measurements. The food-producing species use of such drenches requires attention to withdrawal period assignment under VICH GL 48 metabolism and residue studies. Because oleic acid is an excipient, the active substance’s marker residue depletion governs the withdrawal period. Residue analysis is performed by LC-MS/MS using the marker residue method validated under VICH GL 49. The terminal product is an oral drench for sheep or cattle, typically an endoparasiticide or flukicide in a 1 L high-density polyethylene pack. Storage below 25 °C is required to avoid phase inversion. Freeze-thaw cycling from −5 °C to 40 °C is used to challenge physical stability. A formulation that survives three cycles without cloud point shifting outside the defined specification is considered robust for temperate transport. The main operational boundary is the limited water tolerance of the preconcentrate, which requires the drench to be used without further water dilution by the farm operator. Published data for specific veterinary drench formulations with oleic acid is limited, but the ternary phase approach is widely used in self-emulsifying lipid formulation development.

Dry premix lines for poultry and swine feeds handle oleic acid in a spray-on dust-suppression role rather than as a bulk carrier. The oil is heated to 40–50 °C to reduce viscosity below 50 mPa·s before being metered through a spray nozzle. Droplet size is set at 0.1–0.3 mm to avoid forming sticky aggregates in a ribbon mixer. The addition rate typically ranges from 0.5% to 2.0% by weight of the mineral premix. At addition rates above 3.0% by weight, the premix may form lumps during storage at relative humidity above 70%. A colloidal silica or calcium silicate flow agent is co-added at 0.2–0.5% by weight when the oleic acid load exceeds 2.0%. Mixing after oil addition is limited to 3–5 minutes at 20–40 rpm in a horizontal ribbon mixer. Longer mixing does not improve distribution and can smear oil onto mixer walls. The treated premix is packed in 25 kg bags with an inner polyethylene liner. Premix stability is evaluated by free fatty acid level and peroxide value after 6 months at 25 °C and 60% relative humidity. Vitamin A and vitamin E retention in oil-coated premix is measured by extraction and HPLC according to official AOAC International methods. The terminal product is a vitamin-mineral premix for pig or broiler feed. Batch-to-batch variance in oil droplet distribution is controlled by validating the spray nozzle pressure and pump rate. The major processing bottleneck in field installations is nozzle clogging when the oleic acid is not filtered through a 100 µm in-line filter before spraying. Because oleic acid solidifies below 13 °C, storage tanks and feed lines in cold climate warehouses need heat tracing to maintain 25–30 °C. The dust-suppression effect is quantified by a dustiness tester using a 50 g sample and a 30-second drop. A reduction in airborne particles below 10 µm of at least 60% is a typical in-house target. Published data for specific dust reduction thresholds in veterinary premix formulations is limited because feed mill specifications vary by region and ingredient particle size distribution. The powder product is not a direct medication but a carrier premix; active substances can be added later in the final feed batch, provided the lipid coating does not alter active substance dissolution at the target inclusion rate.

When Oleic Acid Is Added to a Melt Granulation Binder, Product Temperature Must Be Held Below 45 °C During Cooling

Melt granulation is used to produce veterinary granules for oral top dressing or in-feed addition when the active substance is moisture-sensitive. Oleic acid is combined with a solid lipid such as glyceryl behenate or stearic acid at a ratio of 1:5 to 1:3. The lipid blend is melted in a heated vessel at 60–70 °C. The molten binder is sprayed onto a mixed powder bed in a jacketed high-shear granulator. The product temperature is controlled between 45 °C and 55 °C during binder addition to keep the lipid phase workable. End-point is detected by impeller torque. A torque rise of 15–20% above the dry mix baseline indicates that larger granules are forming. The binder level is typically 5–15% by weight of the dry powder. When the binder level exceeds 15%, granules become over-agglomerated and produce a milled fraction with low yield in the target 500–1000 µm size. After the molten binder is added, the granulator jacket temperature is reduced to 20–25 °C. Cooling must bring the product below 40 °C within 20 minutes to avoid amorphous lipid transitions that cause granule sticking during storage. Hardness of the final granule is measured by crushing strength of the 710–1000 µm fraction. Friability is tested by rotating 10 g of granules in a 200 mm diameter drum at 25 rpm for 10 minutes. The acceptable loss is below 1% by weight. Dissolution of the active from lipid granules is evaluated with USP apparatus II at 50 rpm in 900 mL of 0.1 M HCl. The lipid matrix delays release. Release of 80% within 30 minutes is not always achievable without a surfactant pore former such as sodium lauryl sulfate at 0.5–1.0% w/w. These granules are filled into sachets or added to feed at a target inclusion rate of 0.5–5 kg per tonne. Granule density is controlled between 0.6 g/cm³ and 0.8 g/cm³ for uniform metering. A twin-screw extruder with a screw diameter of 16–27 mm and L/D ratio of 25:1 can be used instead of a high-shear granulator for continuous melt granulation. At screw speed below 150 rpm, the residence time may be insufficient for uniform distribution of the molten binder. Barrel zones are set at 50–60 °C and the die plate is cooled to 25–30 °C. The specific energy input is monitored to avoid thermal oxidation of oleic acid. The product temperature at the die must not exceed 65 °C. Published data for specific continuous melt granulation configurations with oleic acid in veterinary applications is limited. Process design is usually based on pharmaceutical lipid granulation literature, and scale-up must be confirmed with at least three pilot batches.

Lipid-Filled Soft Capsule Fill Viscosity and Shell Migration Boundaries

Oleic acid functions as a lipid solvent and viscosity-reducing vehicle in soft gelatin capsules intended for companion animal parasiticides. A fill formulation may contain 10–40% w/w oleic acid in combination with medium-chain triglycerides or propylene glycol monocaprylate. The fill viscosity at 35 °C is a critical parameter for rotary die encapsulation. Viscosity below 100 mPa·s can cause splashing and fill weight variation. Viscosity above 1,000 mPa·s can cause insufficient fill pump filling and cavitation. A target fill viscosity of 200–600 mPa·s at 35 °C is typical for rotary die machines operating at 5–20 rpm. Gelatin ribbon thickness is set at 0.75–1.0 mm to withstand fill migration. Oleic acid migrates into gelatin at fill levels above 40% w/w, softening the shell and increasing oxygen permeability. This migration can be detected by measuring shell water activity and tensile strength after 3 months at 40 °C and 75% relative humidity. Capsule seal integrity is tested by leak testing under vacuum with methylene blue solution. Content uniformity is assessed by USP 905; acceptance value for active content must not exceed 15.0. Dissolution of liquid-filled capsules is performed by USP 711 apparatus II at 75 rpm in 900 mL of 0.1 M HCl with 0.5% sodium lauryl sulfate. The fill matrix emulsifies in the dissolution vessel, releasing the active substance. The terminal product is a soft gelatin capsule in blister packs of 6–12 units. The fill is deaerated under vacuum at 50–60 °C to remove dissolved oxygen before encapsulation. Nitrogen blanketing is maintained in the fill hopper. Oxidation of oleic acid in the fill is controlled by peroxide value and acid value testing after storage. The shell formulation contains a plasticizer system. When oleic acid is part of the fill, excessive plasticizer migration from fill to shell can occur if the fill includes high levels of propylene glycol. The shell and fill are conditioned at 25 °C and 35% relative humidity for 48 hours before sealing. Published data for specific veterinary soft capsule formulations with oleic acid is limited. The mechanical and physical requirements follow general soft capsule technology and pharmacopoeial tests. Capsule fill weight is verified by in-process check weighing every 15–30 minutes during the encapsulation run. A fill weight relative standard deviation below 2.0% is commonly required to meet content uniformity specifications across a batch.

Non-aqueous oral solutions for poultry drinking water lines use oleic acid as a solvent when the active substance is insoluble in propylene glycol but soluble in long-chain fatty acids. A stock solution is prepared by dissolving the active substance in oleic acid at 50–60 °C. The solution is then diluted with a water-miscible co-solvent such as glycerol formal or propylene glycol. The final stock solution contains 30–50% w/w oleic acid. Before administration, the stock solution is diluted into drinking water at 1:500 to 1:2000. Dispersion in drinking water is not a true solution but an emulsion or microdispersion. The diluted product is used within 6–12 hours because the fatty acid phase may separate in the water line. Water hardness above 200 mg/L calcium carbonate can precipitate oleate salts from the dispersion. The drinking water system should be checked for polyvinyl chloride tubing because oleic acid may extract plasticizers from flexible PVC at concentration above 0.1%. The stock solution is packed in amber glass or high-density polyethylene containers and stored below 25 °C. Filtration through a 10 µm polypropylene filter is applied before filling. Assay of the active substance is performed by HPLC with UV detection according to the product monograph. Related substances are limited to below 2.0% total by area normalization. The product must meet the requirements of the regional veterinary medicinal product authorisation for oral solutions. For food-producing species, the user must observe the withdrawal period assigned to the active substance. Oleic acid itself is not the subject of an MRL under EU Regulation 470/2009 because it is not a pharmacologically active substance, but national excipient constraints may apply. The main operational boundary is the freezing point of oleic acid near 13 °C. Stock solutions containing 30–50% oleic acid can become turbid in winter storage and must be warmed to 25–30 °C before metering. The dilution step should not use mild steel piping because free fatty acids can corrode the metal over time. Metering pumps for such stock solutions require seals resistant to fatty acids, such as polytetrafluoroethylene or ethylene propylene diene monomer. The terminal product is a water-miscible liquid concentrate for medicated drinking water. Published data for specific active substances in oleic acid drinking-water concentrates is limited. Formulators rely on solubility screening and stability studies conducted under ICH/VICH conditions to establish safe-use periods and dilution compatibility.